MAPT and Alzheimer disease: We found that VBIT-4 prevented AD-associated pathophysiological changes, including neuronal loss, neuroinflammation, and neuro-metabolic dysfunctions, and the VBIT-4-treated 5 × FAD mice manifested with normal cognitive functions, even when there were no significant changes in phosphorylated-Tau and a ~ 20% decrease in Aβ-plaque load.